Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by RazeKreationson Jan 07, 2022 11:52am
201 Views
Post# 34293148

Opportunities

Opportunities
This from a recent article published on The Financial Post: Small caps could surge: We spend a lot of time looking at this sector. Business is very good, but you would never know it by the prices of some stocks. Many small-cap stocks are down 50 per cent, 60 per cent or even more from their highs. Investors are gaga over Apple Inc. and other trillion-dollar companies, leaving smaller companies behind with low valuations. How low? Based on recent data, small-cap companies, relative to large-cap companies, have never been cheaper. All it takes is a little bit of confidence from investors and small caps could experience big valuation multiple expansions. If not, then we might see a giant wave of takeovers as large companies buy small companies at big discounts. It might be a fun year for small-cap investors, who have been depressed since February, watching large caps surge while their own portfolios struggled. Canadian small cap companies with low valuations can quickly turn into profitable situations, a point made in another recent article published by BNN Bloomberg: Despite the record earnings rebound in 2021, the S&P/TSX Composite Index is still trading at a historical discount to the S&P 500, thus creating an attractive value opportunity in Canada. There couldnt be a better time to turn your attention to Canadian stocks.
<< Previous
Bullboard Posts
Next >>